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Objectives: To refresh clinical diagnostic and therapeutic dilemmas in patients presenting with hepatocellular
cancer (HCC) and to report a rare success of systemic polichemotherapy in metastatic HCC.
Methods: Case report of a patient with successfully resected HCC although initially deemed inoperable according
to current guidelines, and who was successfully treated by systemic polichemotherapy after development of
metastatic disease, resulting in a sustained complete remission.
Results: We describe a 71-year-old female with HCC initially treated by atypical liver resection, although not
amenable to initial surgery according to current treatment guidelines, which resulted in 6 months disease-free
interval. After development of pulmonary metastases, the patient was treated by systemic polichemotherapy, due
to local unavailability of novel biologic agents. After 3 months of chemotherapy biochemical remission was
confirmed, and after 10 months of active treatment complete radiological remission was verified according to
Response Evaluation Criteria in Solid Tumors (RECIST) criteria, now exceeding 9 months in duration.
Conclusion: There is an increasing body of evidence that criteria for surgical interventions in HCC should be
revised and expanded, and our case is an example of such an approach. Although novel biologic therapies are not
widely available in all regions of the world due to their cost, currently there are no hard recommendations for use
of chemotherapy in such areas. Since this is a large problem in clinical practice, we conclude that chemotherapy
should be offered to selected patients of good performance status if novel agents are unavailable.* Correspondence: sbadzek@kbc-zagreb.hr
2Department of Oncology, Division of Gastrointestinal Malignancies,
University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia
Full list of author information is available at the end of the article
© 2013 Rados et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Rados et al. World Journal of Surgical Oncology 2013, 11:236 Page 2 of 5
http://www.wjso.com/content/11/1/236Background
Cancer of the liver is one of most common malignancies
worldwide [1]. It emerges in fields of carcinogenesis in
cirrhotic liver due to any cause, and therefore is one of
paradigms of viral causes of cancer [2-7]. Other risk
factors implied include chronic alcohol consumption,
metabolic liver diseases, cryptogenic cirrhosis, and
aflatoxin B1 [8,9]. It can also occur sporadically in
patients without any identifiable cause, in approxi-
mately 20% of cases.
Since its common presentation is in patients with
severe liver dysfunction, it is one of the deadliest cancers
as well as one of the cancers which are hardest to treat.
In patients with localized disease, main ‘curative’ treat-
ment modalities are surgery, embolization, chemoembo-
lization, radiofrequency ablation and orthotopic liver
transplantation, with liver transplantation being most
beneficial in terms of survival, although some contro-
versy exists whether radical resection should be the
treatment of choice [10,11]. Thirty to forty percent of
patients with localized disease are deemed eligible for
curative intention and are selected according to Milan
criteria, although recently there are published data
suggesting that these criteria should be expanded
[12,13].
However, in patients with metastatic disease, treatment
options remain limited. Historically, chemotherapy was
the only hope for prolongation of life in these patients,
and polichemotherapy has not been shown to be benefi-
cial in terms of survivorship compared to doxorubicin
alone, although better response rates have been reported
[14]. One of the possible reasons is presentation of
disease in patients with severe comorbidities. With the
emergence of novel biologic agents, primarily sorafenib,
response rates became higher and overall survival has
practically doubled, but still remains disappointingly low
[15-17].
Novel biologic agents are very expensive, and there-
fore are not yet available in all parts of the world.Figure 1 Pathohistological review of hepatocellular cancer. Clusters an
angioinvasion are visible, surrounded by healthy liver tissue. Hematoxylin-eRecommendations of the European Society of Medical
Oncology suggest use of chemotherapy in regions
where no other options are available in medically fit
patients [18].
We present a case of sporadic hepatocellular cancer
(HCC), radically resected although not amenable to
Milan criteria, and successfully treated with systemic
chemotherapy after development of metastatic disease,
producing durable complete remission.
Case presentation
A 71-year-old female diabetic patient was diagnosed with
incidental liver mass during liver ultrasound undertaken
for other reasons in a small regional hospital. Initial alpha-
fetoprotein (AFP) was >5000 ng/ml, and after adequate
radiological evaluation (3-phase computed tomography
scan) diagnosis of HCC was established, consisting of four
liver nodules larger than 5 cm. No risk factors for HCC
development were identified. Histological confirmation of
the diagnosis was made, and the patient was referred to
the experienced center (Figure 1). The tumor was classi-
fied as cT3aN0M0, IIIA stage. According to Milan criteria,
the patient was not a candidate for liver transplantation.
Since she was of excellent overall performance status and
had no signs of chronic liver disease, atypical liver resec-
tion was attempted. According to the pathohistological
review, surgical resection was adequate, ensuring >1 cm
margin. Since no signs of the disease were found during
postoperative re-evaluation, no further action was under-
taken. After 6 months follow-up, and increase in AFP level
was detected, and multiple pulmonary metastases were
confirmed on consequent computed tomography and
positron emission tomography scan (Figure 2). The pa-
tient was further treated with polichemotherapy according
to the modified ECF regimen (epirubicin 50 mg/m2 on
day 1, cisplatin 60 mg/m2 on day 1, and 5-fluorouracil
840 mg/m2 on days 1 to 5, given as a 21-day cycle). After
three cycles of chemotherapy, biochemical remission was
confirmed and radiological evaluation revealed a partiald trabeculae of atypical hepatocytes with hyperchromatic nuclei and
osin stain, magnification 400x, of bioptic pathohistological samples.
Figure 2 Fluorodeoxyglucose-positron emission tomography scan of pulmonary metastases. PET scan images reveal two larger
metastases in the right lung: paravertebral (maximal Standardized Uptake Value = 1.9, 16 mm largest diameter) and peripheral subcostal (maximal
Standardized Uptake Value = 2.9, 13 mm diameter), as indicated by white arrows. A few smaller nodules (fluorodeoxyglucose-positron emission
tomography scan negative) in both lungs are also visible.
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when complete radiological remission was confirmed. An
additional two cycles of chemotherapy were given,
completing 1 year of treatment, to eradicate residual
microscopic disease. Today, after 7 months of close
follow-up, the patient is alive and still in complete remis-
sion (exceeding 9 months duration), although experien-
cing mild peripheral neurological toxicity.
Conclusions
HCC is a deadly disease, with 5-year overall survival
below 45% even when treated by liver transplantation in
patients with pTNM stage IVA [19]. Whether current
liver transplantation criteria should be expanded is a
subject of an ongoing debate, as described earlier. On
the other hand, successfully attempting surgical resec-
tion in a patient with locally advanced disease is much
more challenging, and depends primarily on the sur-
geon’s experience. As we described in our patient, suc-
cessful surgical resection was made after referral to an
experienced center, although the patient was diagnosed
and initially deemed inoperable in a small hospital. An-
other thing we would like to emphasize is that it is well
established that radiological and biochemical criteria are
sufficient for diagnosis of HCC. We could speculate that
the relative inexperience of small centers without a con-
sultant oncologist for diagnosis and treatment of HCC
resulted in an unnecessary biopsy, which could be a
possible cause of tumor dissemination. We would like to
emphasize that a consultant oncologist should be invol-
ved in the diagnosis and treatment of patients with can-
cer from the very beginning, which could prove useful in
the improvement of outcomes.
In patients with metastatic disease, treatment options are
limited producing modest improvement in overall survival
of about 3 months in a minority of patients, even when
novel biologic agents are used. Single chemotherapeuticagents which have proven beneficial in terms of response
rate higher than 10% are doxorubicin, 5-fluorouracil and
cisplatin [20].
Polichemotherapy, with the PIAF (cisplatin, interferon-
alpha, doxorubicin, 5-fluorouracil) regimen most com-
monly used, has no proven survival benefit over doxo-
rubicin alone, although it doubles the response rates and
can result in complete pathohistological responses in
patients with initially inoperable HCC at a price of
increased toxicity [21-23]. Since our patient was of
excellent performance status and sorafenib was not
available for treatment of HCC in our country because it
is not covered by the national insurance policy, we de-
cided to try a polichemotherapy regimen, which resulted
in durable complete remission. Since no clear benefit of
interferon therapy has been shown in patients with
metastatic non-viral-related HCC, we treated the patient
with a modified ECF regimen [24,25]. To the best of our
knowledge, this is the first case of complete remission of
metastatic HCC in a patient treated with systemic chemo-
therapy according to the ECF regimen. Only a few
complete responses to tegafur and thalidomide-based
chemotherapy have been described so far [26,27]. Patho-
logical and radiological complete responses are well known
to correlate with better progression-free survival and over-
all survival, which can be supported by our case as well.
Since it has been described that diabetic patients with
HCC treated by metformin have a better prognosis,
maybe this can be attributed to the response seen in our
patient [28]. We could speculate that metformin could
be active in HCC either through mTOR (mammalian
target of rapamycin) inhibition, or by interfering with
the energetic balance of tumor cells by suppression of
oxidative phosphorylation via AMPK (5’ adenosine
monophosphate-activated protein kinase), conse-
quently enhancing the efficiency of chemotherapy in
p53-deficient cells [29,30].
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able tumors should be attempted in patients with
excellent performance status in the hands of experi-
enced surgeons, at least until transplantation criteria
are revised. Maybe chemotherapy should not be left
forgotten as a treatment modality in metastatic HCC,
and should probably be offered to patients with excel-
lent performance status in areas where sorafenib is
unavailable. Chemotherapy efficiency in combination
with metformin should probably be further tested in
clinical trials.
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